# Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma

> **NCT06876142** · PHASE1,PHASE2 · SUSPENDED · sponsor: **National Cancer Institute (NCI)** · enrollment: 54 (estimated)

## Conditions studied

- Multiple Myeloma
- Relapsed and/or Refractory Multiple Myeloma (RRMM)

## Interventions

- **DRUG:** Mirdametinib
- **DRUG:** Sirolimus

## Key facts

- **NCT ID:** NCT06876142
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2026-05-21
- **Primary completion:** 2033-01-01
- **Final completion:** 2033-01-01
- **Target enrollment:** 54 (ESTIMATED)
- **Why stopped:** Administrative hold pending non-safety related changes to the study design.
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06876142

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06876142, "Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06876142. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*